REPL
Replimune Group Inc

3,177
Loading...
Loading...
News
all
press releases
REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug
Replimune stock dives 54% over three months after the FDA rejects its RP1/Opdivo melanoma drug filing, delaying its first potential product launch.
Zacks·13d ago
News Placeholder
More News
News Placeholder
Replimune Stock Plunged 42% Today – Here’s Why
The company stated that it is evaluating feedback from the FDA regarding the approval of its lead candidate for the treatment of advanced melanoma to determine its next course of action.
Stocktwits·19d ago
News Placeholder
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit - REPL
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit - REPL Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of...
PR Newswire·2mo ago
News Placeholder
Replimune Stock Catches Retail Fire As Analyst Says FDA Shakeup Removes 'Major Obstacle' For Skin Cancer Drug's Potential Approval
Analysts believe the resignation of a top FDA official could lead to a reversal of the melanoma drug rejection, which was based on trial design concerns.
Stocktwits·2mo ago
News Placeholder
REPL Stock Nearly Doubled In Value Today: What's Going On?
Prasad stepped down as the Director of the Center for Biologics Evaluation and Research (CBER) on Tuesday, nearly three months into the job.
Stocktwits·2mo ago
News Placeholder
Replimune Stock Hits 1-Year High In After-hours As Small-Cap Biotech Files For FDA Approval Of Skin Cancer Combo Therapy: Retail Upbeat
Replimune’s lead asset RP1 is based on a proprietary new strain of Herpes simplex virus engineered to maximize tumor killing potency.
Stocktwits·11mo ago
News Placeholder
Replimune Group presents interim results from ARTACUS trial of RP1 monotherapy
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·1y ago
News Placeholder
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
RP1 monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent and complete response rate of nearly 22 percent in evaluable patientsSAN DIEGO, April 07, 2024...
Globe Newswire·1y ago
News Placeholder
Replimune Group announces inducement grants under Nasdaq listing rule
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WOBURN, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic...
Globe Newswire·2y ago

Latest REPL News

View

Advertisement|Remove ads.

Advertisement|Remove ads.